![Page 1: HBsAg quantification in clinical practice - PHC · HBsAg quantification in clinical practice Pr Albert TRAN, Hôpital l’Archet 2, Nice, France Dr Denis OUZAN, Institut Arnault Tzanck,](https://reader031.vdocuments.us/reader031/viewer/2022012920/5b994e9809d3f2085f8d6aec/html5/thumbnails/1.jpg)
HBsAg quantification in clinical practice
Pr Albert TRAN, Hôpital l’Archet 2, Nice, FranceDr Denis OUZAN, Institut Arnault Tzanck, Saint
Laurent du Var, France
![Page 2: HBsAg quantification in clinical practice - PHC · HBsAg quantification in clinical practice Pr Albert TRAN, Hôpital l’Archet 2, Nice, France Dr Denis OUZAN, Institut Arnault Tzanck,](https://reader031.vdocuments.us/reader031/viewer/2022012920/5b994e9809d3f2085f8d6aec/html5/thumbnails/2.jpg)
Disclosure (A. Tran)
• BMS• Gilead• Merck• Abbvie• Janssen
![Page 3: HBsAg quantification in clinical practice - PHC · HBsAg quantification in clinical practice Pr Albert TRAN, Hôpital l’Archet 2, Nice, France Dr Denis OUZAN, Institut Arnault Tzanck,](https://reader031.vdocuments.us/reader031/viewer/2022012920/5b994e9809d3f2085f8d6aec/html5/thumbnails/3.jpg)
HBV lifecycle
Chan H et al. J Hepatol 2011;55:1121
![Page 4: HBsAg quantification in clinical practice - PHC · HBsAg quantification in clinical practice Pr Albert TRAN, Hôpital l’Archet 2, Nice, France Dr Denis OUZAN, Institut Arnault Tzanck,](https://reader031.vdocuments.us/reader031/viewer/2022012920/5b994e9809d3f2085f8d6aec/html5/thumbnails/4.jpg)
Correlation between qHBsAg, cccDNA and HBV DNA
HBsAg and genotype
The correlation between HBsAg and HBV DNA inserum wasnoticed also within thegenotypes(Fig. 3A–D),but this correlation was not significant in genotype Apatients. HBsAg levels were higher in patients carryingHBV genotype C, but this difference mainly reflected thehigher rate of HBeAg positivity. If the patients weregrouped according to HBeAg status, as shown inFigure 3E, the levels of HBsAg did not differ significantlybetween the different genotypes, neither in the HBeAg-positive nor in the HBeAg-negative group. The HBVDNA/HBsAg ratio (log1 0 value difference) was lower inHBeAg-negative patients infected with genotype A (0.63)as compared with B (1.24), C (1.23) or D (1.38,P = 0.004). Accordingly, HBsAg levels in the IC groupwere lower in genotype D than in genotype A (2.62 vs.3.38 log1 0 IU/ml, P = 0.01).
Discussion
Recent reports indicate that HBsAgquantification mightbeauseful complement to HBV DNA quantification forclinical assessment and treatment monitoring inpatients with chronic HBV infection (3, 17, 18). Therationale for this is the fact that subviral particles(HBsAg) and virions (HBV DNA) are synthesized viadifferent pathways, and therefore may reflect liver viralload and viral suppression differently.
This study confirms the previously described associa-tion between HBsAg levels and clinical stage, and alsoshowsan association with liver inflammation assessed byhistological scoring and ALT. Given that an associationbetween HBV DNA and liver damage iswell known thiswas not surprising, but some previous studies have notfound an association between HBsAg and ALT (8), andstudiesof HBsAg levelsand histological scoresarerare.
HB
V D
NA
(lo
g c
opie
s/m
l) –
HB
sAg
(log
IU/m
l)
e+AC e-AC IC
–1
0
1
2
3
4
5
6
–2
HB
V D
NA
(lo
g co
pie
s/m
l)/H
BsA
g (
log
IU/m
l)e+AC e-AC IC
5
4
3
2
1
0
1110
98765
HBeAg–HBeAg+
4321
HB
V D
NA
(lo
g co
pies
/ml)
–6cccDNA/cEq
–5
HBV DNA BL = 8.318 + 1.42 * cccDNA/cell; Rˆ2 = .609
–4 –3 –2 –1 0 1
HBeAg–HBeAg+
HB
sAg
(lo
g IU
/ml)
cccDNA/cEqHBsAg BL = 4.84 + .542 * cccDNA/cell; Rˆ2 = .411
0
1
2
3
4
5
6
–6 –5 –4 –3 –2 –1 0 1
HBeAg–HBeAg+
HB
sAg
(log
IU/m
l)
HBV DNA (log copies/ml)HBsAg BL = 2.221 + .279 * HBV DNA BL; Rˆ2 = .387
0
1
2
3
4
5
6
1 2 3 4 5 6 7 8 9 10 11
HB
sAg
(log
IU/m
l)
Age (years)HBsAg BL = 4.516 - .024 * Age; Rˆ2 = .068
0
1
2
3
4
5
6
10 20 30 40 50 60 70
(A) (D)
(B) (E)
(C) (F)
Fig. 1. Correlation between cccDNA, HBsAg and HBV DNA (A-C). Impact of clinical stage on the ratio between HBV DNA and HBsAg(D shows log ratio, Eshows ratio of log values). Fshows correlation between HBsAg and age.
Liver International (2013)© 2013 John Wiley & SonsA/S. Published by John Wiley & SonsLtd4
HBsAg, liver damage and clinical staging of chronic HBV infect ion Larsson et al.
HBsAg and genotype
The correlation between HBsAg and HBV DNA inserum wasnoticed also within thegenotypes(Fig. 3A–D),but this correlation was not significant in genotype Apatients. HBsAg levels were higher in patients carryingHBV genotype C, but this difference mainly reflected thehigher rate of HBeAg positivity. If the patients weregrouped according to HBeAg status, as shown inFigure 3E, the levels of HBsAg did not differ significantlybetween the different genotypes, neither in the HBeAg-positive nor in the HBeAg-negative group. The HBVDNA/HBsAg ratio (log1 0 value difference) was lower inHBeAg-negative patients infected with genotype A (0.63)as compared with B (1.24), C (1.23) or D (1.38,P = 0.004). Accordingly, HBsAg levels in the IC groupwere lower in genotype D than in genotype A (2.62 vs.3.38 log1 0 IU/ml, P = 0.01).
Discussion
Recent reports indicate that HBsAg quantification mightbeauseful complement to HBV DNA quantification forclinical assessment and treatment monitoring inpatients with chronic HBV infection (3, 17, 18). Therationale for this is the fact that subviral particles(HBsAg) and virions (HBV DNA) are synthesized viadifferent pathways, and therefore may reflect liver viralload and viral suppression differently.
This study confirms the previously described associa-tion between HBsAg levels and clinical stage, and alsoshowsan association with liver inflammation assessed byhistological scoring and ALT. Given that an associationbetween HBV DNA and liver damage iswell known thiswas not surprising, but some previous studies have notfound an association between HBsAg and ALT (8), andstudiesof HBsAg levelsand histological scoresarerare.
HB
V D
NA
(lo
g co
pies
/ml)
– H
BsA
g(lo
g IU
/ml)
e+AC e-AC IC
–1
0
1
2
3
4
5
6
–2
HB
V D
NA
(lo
g co
pies
/ml)/
HB
sAg
(log
IU/m
l)
e+AC e-AC IC
5
4
3
2
1
0
1110
98765
HBeAg–HBeAg+
4321
HB
V D
NA
(lo
g co
pies
/ml)
–6cccDNA/cEq
–5
HBV DNA BL = 8.318 + 1.42 * cccDNA/cell; Rˆ2 = .609
–4 –3 –2 –1 0 1
HBeAg–HBeAg+
HB
sAg
(log
IU/m
l)
cccDNA/cEqHBsAg BL = 4.84 + .542 * cccDNA/cell; Rˆ2 = .411
0
1
2
3
4
5
6
–6 –5 –4 –3 –2 –1 0 1
HBeAg–HBeAg+
HB
sAg
(log
IU/m
l)HBV DNA (log copies/ml)
HBsAg BL = 2.221 + .279 * HBV DNA BL; Rˆ2 = .387
0
1
2
3
4
5
6
1 2 3 4 5 6 7 8 9 10 11
HB
sAg
(log
IU/m
l)
Age (years)HBsAg BL = 4.516 - .024 * Age; Rˆ2 = .068
0
1
2
3
4
5
6
10 20 30 40 50 60 70
(A) (D)
(B) (E)
(C) (F)
Fig. 1. Correlation between cccDNA, HBsAg and HBV DNA (A-C). Impact of clinical stage on the ratio between HBV DNA and HBsAg(D shows log ratio, Eshows ratio of log values). Fshowscorrelation between HBsAg and age.
Liver International (2013)© 2013 John Wiley & SonsA/S. Published by John Wiley & SonsLtd4
HBsAg, liver damage and clinical staging of chronic HBV infect ion Larsson et al.
Larsson S et al. Liver Int 2013 (in press)
![Page 5: HBsAg quantification in clinical practice - PHC · HBsAg quantification in clinical practice Pr Albert TRAN, Hôpital l’Archet 2, Nice, France Dr Denis OUZAN, Institut Arnault Tzanck,](https://reader031.vdocuments.us/reader031/viewer/2022012920/5b994e9809d3f2085f8d6aec/html5/thumbnails/5.jpg)
qHBsAg and genotypes A and D
Jaroszewicz et al. J Hepatol 2010;52:514
![Page 6: HBsAg quantification in clinical practice - PHC · HBsAg quantification in clinical practice Pr Albert TRAN, Hôpital l’Archet 2, Nice, France Dr Denis OUZAN, Institut Arnault Tzanck,](https://reader031.vdocuments.us/reader031/viewer/2022012920/5b994e9809d3f2085f8d6aec/html5/thumbnails/6.jpg)
qHBsAg and HBV DNA in acute hepatitis B
Jaroszewicz et al. J Hepatol 2010;52:514
![Page 7: HBsAg quantification in clinical practice - PHC · HBsAg quantification in clinical practice Pr Albert TRAN, Hôpital l’Archet 2, Nice, France Dr Denis OUZAN, Institut Arnault Tzanck,](https://reader031.vdocuments.us/reader031/viewer/2022012920/5b994e9809d3f2085f8d6aec/html5/thumbnails/7.jpg)
qHBsAg in clinical practice
• Combined with HBV DNA• Chronic Hepatitis B
– Natural history (A. TRAN)– Treatment (D. Ouzan)
![Page 8: HBsAg quantification in clinical practice - PHC · HBsAg quantification in clinical practice Pr Albert TRAN, Hôpital l’Archet 2, Nice, France Dr Denis OUZAN, Institut Arnault Tzanck,](https://reader031.vdocuments.us/reader031/viewer/2022012920/5b994e9809d3f2085f8d6aec/html5/thumbnails/8.jpg)
Questions
• Do you measure qHBsAg in complement of HBV DNA in routine (follow up)?
– Yes– No
![Page 9: HBsAg quantification in clinical practice - PHC · HBsAg quantification in clinical practice Pr Albert TRAN, Hôpital l’Archet 2, Nice, France Dr Denis OUZAN, Institut Arnault Tzanck,](https://reader031.vdocuments.us/reader031/viewer/2022012920/5b994e9809d3f2085f8d6aec/html5/thumbnails/9.jpg)
Case report• 32 yrs old• Female• Caucasian• No familial history of liver cancer• Liver US exam: normal• ALT 24 UI/L, AST 22 UI/L• Platelet 250 000/mm3• HBV DNA < 20 UI/mL• e negative• qHBsAg 45 UI/mL
![Page 10: HBsAg quantification in clinical practice - PHC · HBsAg quantification in clinical practice Pr Albert TRAN, Hôpital l’Archet 2, Nice, France Dr Denis OUZAN, Institut Arnault Tzanck,](https://reader031.vdocuments.us/reader031/viewer/2022012920/5b994e9809d3f2085f8d6aec/html5/thumbnails/10.jpg)
The adding value of qHBsAg in natural history
• Prediction of inactive carrier • Prediction of HBs loss• Prediction of liver fibrosis and cellular
hepatocarcinoma
![Page 11: HBsAg quantification in clinical practice - PHC · HBsAg quantification in clinical practice Pr Albert TRAN, Hôpital l’Archet 2, Nice, France Dr Denis OUZAN, Institut Arnault Tzanck,](https://reader031.vdocuments.us/reader031/viewer/2022012920/5b994e9809d3f2085f8d6aec/html5/thumbnails/11.jpg)
Inactive carrier and CAH HBe-
Martinot-Peignoux M et al. Ann Biol Clin 2013
![Page 12: HBsAg quantification in clinical practice - PHC · HBsAg quantification in clinical practice Pr Albert TRAN, Hôpital l’Archet 2, Nice, France Dr Denis OUZAN, Institut Arnault Tzanck,](https://reader031.vdocuments.us/reader031/viewer/2022012920/5b994e9809d3f2085f8d6aec/html5/thumbnails/12.jpg)
qHBsAg according to diferent replicative phases of CHB
Martinot-Peignoux M et al. Ann Biol Clin 2013
![Page 13: HBsAg quantification in clinical practice - PHC · HBsAg quantification in clinical practice Pr Albert TRAN, Hôpital l’Archet 2, Nice, France Dr Denis OUZAN, Institut Arnault Tzanck,](https://reader031.vdocuments.us/reader031/viewer/2022012920/5b994e9809d3f2085f8d6aec/html5/thumbnails/13.jpg)
Brunetto MR et al Gastroenterology 2010;139:483
qHBsAg and genotype D inactive carriers
Prediction of Inactive carrier
qHBsAgHBV-DNA
<1000 IU/mL <2000 IU/mL
HBs Carriers (IC) 209 (56)
Diagnostic accuracy 91.1%Sensibility 91.1%
Specificity 95.4%
PPV 87.9%
NPV 96.7%
![Page 14: HBsAg quantification in clinical practice - PHC · HBsAg quantification in clinical practice Pr Albert TRAN, Hôpital l’Archet 2, Nice, France Dr Denis OUZAN, Institut Arnault Tzanck,](https://reader031.vdocuments.us/reader031/viewer/2022012920/5b994e9809d3f2085f8d6aec/html5/thumbnails/14.jpg)
Inactive carriers: qAgHBs < 1000 UI/mL
and HBV DNA < 2000 UI/mL
qHBsAg and inactive carriers
![Page 15: HBsAg quantification in clinical practice - PHC · HBsAg quantification in clinical practice Pr Albert TRAN, Hôpital l’Archet 2, Nice, France Dr Denis OUZAN, Institut Arnault Tzanck,](https://reader031.vdocuments.us/reader031/viewer/2022012920/5b994e9809d3f2085f8d6aec/html5/thumbnails/15.jpg)
HBsAg (log IU/ml)
Immunotolerance (7)
HBeAg+ (25)
e seroconversion (17)
CHB HBeAg- (46)
Inactive carrier (22)
Chan HL, et al. Hepatology 2010
117 Patients FU 99±16 mois
Long term follow up of qHBsAg
![Page 16: HBsAg quantification in clinical practice - PHC · HBsAg quantification in clinical practice Pr Albert TRAN, Hôpital l’Archet 2, Nice, France Dr Denis OUZAN, Institut Arnault Tzanck,](https://reader031.vdocuments.us/reader031/viewer/2022012920/5b994e9809d3f2085f8d6aec/html5/thumbnails/16.jpg)
Avec l’aimable autorisation de Denis Ouzan
qHBsAG can predict the loss of HBsAG
Tseng et al, Gastroenterology 2011
1 3 5 7 9 11 13 15 ans
020
4060
80 %
Incidence of spontaneous loss of HBsAg
HBsAg < 100 UI/ml
HBsAg100-999 UI/ml
HBsAg > 1000 UI/ml
![Page 17: HBsAg quantification in clinical practice - PHC · HBsAg quantification in clinical practice Pr Albert TRAN, Hôpital l’Archet 2, Nice, France Dr Denis OUZAN, Institut Arnault Tzanck,](https://reader031.vdocuments.us/reader031/viewer/2022012920/5b994e9809d3f2085f8d6aec/html5/thumbnails/17.jpg)
HBsAg seroclearance stratified by HBV DNA levels in Hbe- patients infected by genotype B and C
qHBsAg (IU/mL) HBV DNA*≥ 2000 UI/mL
(n=837)
HBV DNA*Detectable-1999 UI/mL (n=935)
HBV DNA*Undetectable
(n=719)
≥ 1000 1 1 1
100-999 1.84 (1.04-3.25)
4.26 (2.49-7.28)
10.22 (3.62-28.86)
<100 6.04 (3.23-11.31)
8.88 (5.30-14.89)
38.93 (14.47-104.73)
*adjusted rate ratio (95% CI)
Liu J et al. J Hepatol 2013;58:853
![Page 18: HBsAg quantification in clinical practice - PHC · HBsAg quantification in clinical practice Pr Albert TRAN, Hôpital l’Archet 2, Nice, France Dr Denis OUZAN, Institut Arnault Tzanck,](https://reader031.vdocuments.us/reader031/viewer/2022012920/5b994e9809d3f2085f8d6aec/html5/thumbnails/18.jpg)
Changes in qHBsAg prior to HBsAg seroclearance
Undetectable HBV DNA Detectable HBV DNA
Liu J et al. J Hepatol 2013;58:853
![Page 19: HBsAg quantification in clinical practice - PHC · HBsAg quantification in clinical practice Pr Albert TRAN, Hôpital l’Archet 2, Nice, France Dr Denis OUZAN, Institut Arnault Tzanck,](https://reader031.vdocuments.us/reader031/viewer/2022012920/5b994e9809d3f2085f8d6aec/html5/thumbnails/19.jpg)
qHBsAG according to the fibrosis severity
Martinot-Peignoux M et al. J Hepatol 2013;58:1089Seto WK et al. Plos One 2012;7:e43087
qHBsAG 3.85 log IU (gen B or C) : NPV 91%, ≤ F1 - > F1
![Page 20: HBsAg quantification in clinical practice - PHC · HBsAg quantification in clinical practice Pr Albert TRAN, Hôpital l’Archet 2, Nice, France Dr Denis OUZAN, Institut Arnault Tzanck,](https://reader031.vdocuments.us/reader031/viewer/2022012920/5b994e9809d3f2085f8d6aec/html5/thumbnails/20.jpg)
Ratio GGT to qHBsAg to predict significant fibrosis among e positive patients
Xun YH et al. J Gastroenterol Hepatol 2013;28:1746
![Page 21: HBsAg quantification in clinical practice - PHC · HBsAg quantification in clinical practice Pr Albert TRAN, Hôpital l’Archet 2, Nice, France Dr Denis OUZAN, Institut Arnault Tzanck,](https://reader031.vdocuments.us/reader031/viewer/2022012920/5b994e9809d3f2085f8d6aec/html5/thumbnails/21.jpg)
HBV DNA an independent risk factor for HCC and cirrhosis : REVEAL study
• HBV DNA level was a strong predictor of HCC1 and cirrhosis2, independent of HBeAg status and serum ALT
1. Chen CJ, et al. JAMA. 2006; 295:65-73. 2. Iloeje UH, et al. Gastroenterology 2006; 130:678-686.
Year of follow-up
Cu
mu
lati
ve
inc
ide
nc
e o
f H
CC
(%
) 15%
1.3–1.4%
4%
12%
Entire cohort N=3653
Patient age distribution: 30−39 years: 33%; 40−49 years: 28%; 50−59 years: 29%; � 60 years: 10%
![Page 22: HBsAg quantification in clinical practice - PHC · HBsAg quantification in clinical practice Pr Albert TRAN, Hôpital l’Archet 2, Nice, France Dr Denis OUZAN, Institut Arnault Tzanck,](https://reader031.vdocuments.us/reader031/viewer/2022012920/5b994e9809d3f2085f8d6aec/html5/thumbnails/22.jpg)
Incidence of HCC and qHBsAg in HBe- patients with low viral load (< 2000 IU/mL)
Tseng TC et al. Gastroenterology 2012;142:1140
Adj. HR 13.7 (95%CI 4.8-39.3)